MA33260B1 - 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines - Google Patents

6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines

Info

Publication number
MA33260B1
MA33260B1 MA34332A MA34332A MA33260B1 MA 33260 B1 MA33260 B1 MA 33260B1 MA 34332 A MA34332 A MA 34332A MA 34332 A MA34332 A MA 34332A MA 33260 B1 MA33260 B1 MA 33260B1
Authority
MA
Morocco
Prior art keywords
azabicyclo
hex
phenylpyrimidines
platletary
cerebrovascular
Prior art date
Application number
MA34332A
Other languages
English (en)
Inventor
Eva Caroff
Kurt Hilpert
Francis Hubler
Emmanuel Meyer
Dorte Renneberg
Original Assignee
Actelion Pharmaceuticals Ltd
Saba & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Saba & Co filed Critical Actelion Pharmaceuticals Ltd
Publication of MA33260B1 publication Critical patent/MA33260B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION PORTE SUR DES DÉRIVÉS 6-(3-AZABICYCLO[3.1.0]HEX-3-YL)-2-PHÉNYLPYRIMIDINES ET SUR LEUR UTILISATION COMME ANTAGONISTES DU RÉCEPTEUR P2Y12 DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES VASCULAIRES PÉRIPHÉRIQUES, VISCÉRALES, HÉPATIQUES ET VASCULAIRES RÉNALES, CARDIOVASCULAIRES ET CÉRÉBROVASCULAIRES OU D'AFFECTIONS ASSOCIÉES À L'AGRÉGATION PLAQUETTAIRE, DONT LA THROMBOSE CHEZ L'HOMME ET D'AUTRES MAMMIFÈRES.
MA34332A 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines MA33260B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009051486 2009-04-08
PCT/IB2010/051499 WO2010116328A2 (fr) 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0]hex-3-yl)-2-phénylpyrimidines

Publications (1)

Publication Number Publication Date
MA33260B1 true MA33260B1 (fr) 2012-05-02

Family

ID=42936647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34332A MA33260B1 (fr) 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines

Country Status (18)

Country Link
US (1) US8288385B2 (fr)
EP (1) EP2417128B1 (fr)
JP (1) JP5536873B2 (fr)
KR (1) KR101694563B1 (fr)
CN (1) CN102369197B (fr)
AU (1) AU2010233378A1 (fr)
BR (1) BRPI1014039A2 (fr)
CA (1) CA2756542C (fr)
CL (1) CL2011002467A1 (fr)
ES (1) ES2567311T3 (fr)
IL (1) IL215517A0 (fr)
MA (1) MA33260B1 (fr)
MX (1) MX2011010200A (fr)
NZ (1) NZ596213A (fr)
RU (1) RU2011144763A (fr)
SG (1) SG175075A1 (fr)
WO (1) WO2010116328A2 (fr)
ZA (1) ZA201108158B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
EP2421859B1 (fr) 2009-04-22 2014-04-09 Actelion Pharmaceuticals Ltd. Dérivés de thiazole et leurs utilisation comme antagonistes du recepteur p2y12
NZ628587A (en) 2012-03-06 2016-07-29 Boehringer Ingelheim Int Benzodioxanes in combination with other actives for inhibiting leukotriene production
EP2968737A4 (fr) * 2013-03-15 2016-11-09 Concert Medical Llc Procédé et système permettant l'administration de fluide à un patient et/ou le retrait de fluide d'un patient, de façon contrôlable
SI3397631T1 (sl) * 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
ES2886840T3 (es) 2016-08-31 2021-12-21 Eisai R&D Man Co Ltd Compuesto de pirazolo[1,5-a]pirimidina
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
PH12021551635A1 (en) 2019-01-29 2022-05-02 Shandong Xuanzhu Pharma Co Ltd Hexone glucokinase inhibitor and use thereof
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
GB202001856D0 (en) * 2020-02-11 2020-03-25 Inorbit Therapeutics Ab Compounds useful in inhibiting ketohexokinase and methods of making and using the same
CA3188340A1 (fr) 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Traitement de la deficience cognitive associee a la schizophrenie
CA3195702A1 (fr) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Procede de retraitement

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
OA12970A (en) * 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
CA2521313A1 (fr) 2003-04-09 2004-10-28 Wyeth Derives d'acide phosphonique 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non- 1(7)-en-2-yl)-alkyl et leurs methodes d'utilisation
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
WO2007046075A1 (fr) 2005-10-21 2007-04-26 Actelion Pharmaceuticals Ltd Derives de piperazine utilises comme agents antimalaria
WO2008031556A2 (fr) 2006-09-12 2008-03-20 Ucb Pharma, S.A. Nouveaux dérivés de la 2-amino-pyrimidine, procédés pour les préparer, compositions pharmaceutiques les contenant
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
KR20100015886A (ko) 2007-04-23 2010-02-12 사노피-아벤티스 Ｐ2ｙ12 길항제로서의 퀴놀린-카복스아미드 유도체
TW200911787A (en) * 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
EP2238128B1 (fr) 2007-12-26 2012-08-22 Sanofi Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
WO2009080227A2 (fr) 2007-12-26 2009-07-02 Sanofi-Aventis Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
EP2421859B1 (fr) 2009-04-22 2014-04-09 Actelion Pharmaceuticals Ltd. Dérivés de thiazole et leurs utilisation comme antagonistes du recepteur p2y12

Also Published As

Publication number Publication date
SG175075A1 (en) 2011-11-28
CN102369197A (zh) 2012-03-07
RU2011144763A (ru) 2013-05-20
US20120028989A1 (en) 2012-02-02
ZA201108158B (en) 2014-04-30
JP5536873B2 (ja) 2014-07-02
CN102369197B (zh) 2013-11-06
ES2567311T3 (es) 2016-04-21
NZ596213A (en) 2013-05-31
MX2011010200A (es) 2011-10-14
WO2010116328A3 (fr) 2011-01-13
CA2756542C (fr) 2017-08-22
CL2011002467A1 (es) 2012-02-24
EP2417128A2 (fr) 2012-02-15
JP2012523406A (ja) 2012-10-04
EP2417128B1 (fr) 2016-03-02
AU2010233378A1 (en) 2011-11-24
WO2010116328A2 (fr) 2010-10-14
BRPI1014039A2 (pt) 2018-04-03
US8288385B2 (en) 2012-10-16
KR101694563B1 (ko) 2017-01-09
IL215517A0 (en) 2011-12-29
CA2756542A1 (fr) 2010-10-14
KR20120070627A (ko) 2012-06-29

Similar Documents

Publication Publication Date Title
MA33260B1 (fr) 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
MA32277B1 (fr) Derives de 2-phenyl-4- cyclopropyl-pyrimidine
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
MA33277B1 (fr) Dérivés de thiazole et leur utilisation comme antagonistes des récepteurs p2y12
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MY165273A (en) Anti-cd48 antibodies and uses thereof
MX2009004186A (es) Derivados de 2-fenil-6-aminocarbonil-pirimidina.
TW200640877A (en) Pyrimidine derivatives
EA201291441A1 (ru) Пробиотические штаммы для применения при улучшении состояния кишечной нервной системы
MY153749A (en) Phosphonic acid derivates and their use as p2y12 receptor antagonists
UA102065C2 (xx) Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
EP2486060A4 (fr) Anticorps anti-siglec 15 dans le traitement de maladies liées à une perte osseuse
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EP2485751A4 (fr) Procédés de traitement de la dépression et d'autres maladies associées
EA201270480A1 (ru) Новые соединения
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
EA201390830A1 (ru) Соединения и их применение в качестве ингибиторов фермента расщепления бета-сайта app (bace)
WO2011141823A3 (fr) Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
MX364200B (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі